The US National Institute of Health (NIH) has launched a search for neuroprotective therapies to reduce ischemic brain injury.
The US National Institute of Health (NIH) has launched a search for neuroprotective therapies to reduce ischemic brain injury.
Go deeper with GlobalData
The NIH will fund a preclinical trial platform that will test treatments for ischemic stroke in rodents. Over the next three years, it will give $4m for the network.
Under the Stroke Preclinical Assessment Network (SPAN), seven labs will work in tandem with each other and make use of different clinical trial practices to assess the effectiveness of the six neuroprotective therapies.
NIH National Institute of Neurological Disorders and Stroke director Walter J Koroshetz said: “Our primary goal is to identify the most promising treatments for testing in patients with clinical trials. In the long term, we hope that this approach will increase the chance of success in pairing a brain saving treatment with the current practice of clot removal used to treat patients with potentially fatal or disabling stroke.”
The existing treatments for ischemic brain injury dissolve clot using blood thinner injections or direct extraction of the clot.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataStudies have shown that there is a possibility of damage before or during these procedures.
Recent reports have suggested that some labs fail in replicating the preclinical treatments in humans. To tackle this, the NIH has been working on a project entitled Rigor and Reproducibility to make the preclinical trial results to be more like those of clinical trials.
NINDS Program director Francesca Bosetti said: “This SPAN trial will take the principles laid out in NIH’s Rigor and Reproducibility guidelines one step further. The network will use clinical trial practices and standards to search for the neuroprotective stroke therapies that have the greatest potential for working in humans.”
In June this year, the NIH agreed to fund clinical trials investigating the practicality and effectiveness of using genomics data as part of treatments for chronic diseases.
